- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05377320
Patientlikhet för beslutsfattande i förebyggande av kardiovaskulär toxicitet (PACT): En genomförbarhetsstudie
This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists, will favorably impact appropriate medication use and cardiac imaging surveillance, and will improve clinician and patient decision-making, perception, and behavior towards cardioprotective medication usage and cardiovascular disease imaging utilization.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
For this feasibility study, the researchers will create the clinical decision aid and test the central hypothesis that this novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists and will favorably impact appropriate medication use and cardiac imaging surveillance. The hypothesis is supported by preliminary data suggesting that an initial and rudimentary version of the clinical aid increases appropriate medication use and imaging follow-up in cardio-oncology patients. Success will be determined by ≥85% of clinic visits using the clinical decision aid resulting in pursuit of medication use and cardiac imaging surveillance patterns commensurate with recommendations specific to cancer survivors, with overall rates the same or higher than the group without the clinical decision aid, as well as overall favorable patient and physician focus group comments and survey responses.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Yee Chung Cheng, MD
- Telefonnummer: 414-805-4600
- E-post: ycheng@mcw.edu
Studieorter
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Froedtert & the Medical College of Wisconsin
-
Huvudutredare:
- Yee Chung Chen, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Cancer survivors at intermediate, high, or very high risk for developing cardiovascular disease will pursue a cardio-oncology visit.
Beskrivning
Inclusion Criteria:
- Patients ≥18 years with a history of cancer.
- Have not previously visited a cardiologist to assess cardiovascular risk after cancer diagnosis.
- Clinically at intermediate, high, or very high risk for cardiovascular diseases determined based on imprecise clinical risk models, such as those used for cardiac dysfunction.
- Ability to understand a written informed consent form, and willing to sign it prior to study registration.
Exclusion Criteria:
- Patient <18 years.
- Without a personal history of cancer.
- Existing cardiomyopathy diagnosed after cancer diagnosis.
- Documented cognitive impairment.
- Patient or patient representative who is unable and unwilling to sign the informed consent form.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Clinical Decision Aid Group
In this group, physicians will use standard care plus the clinical decision aid. |
The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24. |
|
Control Group
In this group, physicians will use standard care only. |
Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Medication use
Tidsram: Week 0
|
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 0
|
|
Medication use
Tidsram: Week 12
|
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 12
|
|
Medication use
Tidsram: Week 24
|
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 24
|
|
Imaging surveillance
Tidsram: Week 0
|
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 0
|
|
Imaging surveillance
Tidsram: Week 12
|
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 12
|
|
Imaging surveillance
Tidsram: Week 24
|
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 24
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Yee Chung Cheng, MD, Medical College of Wisconsin
Publikationer och användbara länkar
Allmänna publikationer
- Brown SA, Chung BY, Doshi K, Hamid A, Pederson E, Maddula R, Hanna A, Choudhuri I, Sparapani R, Bagheri Mohamadi Pour M, Zhang J, Kothari AN, Collier P, Caraballo P, Noseworthy P, Arruda-Olson A; Cardio-Oncology Artificial Intelligence Informatics and Precision Equity (CAIPE) Research Team Investigators. Patient similarity and other artificial intelligence machine learning algorithms in clinical decision aid for shared decision-making in the Prevention of Cardiovascular Toxicity (PACT): a feasibility trial design. Cardiooncology. 2023 Jan 23;9(1):7. doi: 10.1186/s40959-022-00151-0.
- Brown SA, Hamid A, Pederson E, Bs AH, Maddula R, Goodman R, Lamberg M, Caraballo P, Noseworthy P, Lukan O, Echefu G, Berman G, Choudhuri I; Cardio-Oncology Artificial Intelligence Informatics & Precision Equity (CAIPE) and Patient Similarity Algorithms in the Prevention of Cardiovascular Toxicity (PACT) Research Team Investigators. Simplified rules-based tool to facilitate the application of up-to-date management recommendations in cardio-oncology. Cardiooncology. 2023 Oct 27;9(1):37. doi: 10.1186/s40959-023-00179-w.
- Brown SA, Fang MZ, Sparapani R, Zhou Y, Osinski K, Taylor B, Yu D, Blessing J, Shah R, Collier P, BagheriMohamadiPour M, Zhang J, Kothari A, Echefu G, Rickards J, Otto C, Sanchez Z, Olson J, Arruda-Olson A, Cheng YC, Cheng F; Cardio-Oncology Artificial Intelligence Informatics and Precision Equity, and Patient Similarity Algorithms in the Prevention of Cardiovascular Toxicity Research Team Investigators. PrevCardioOncAI: Machine Learning Algorithms for Predicting Cardiovascular Disease in Cancer Survivors. J Am Heart Assoc. 2025 Dec 16;14(24):e030363. doi: 10.1161/JAHA.123.030363. Epub 2025 Dec 11.
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Sjukdomar i det endokrina systemet
- Kärlsjukdomar
- Hjärt-kärlsjukdomar
- Sår och skador
- Patologiska processer
- Hjärtsjukdom
- Metaboliska sjukdomar
- Störningar i glukosmetabolism
- Kemiskt inducerade störningar
- Läkemedelsrelaterade biverkningar och biverkningar
- Strålningsskador
- Åderförkalkning
- Arterioskleros
- Arteriella ocklusiva sjukdomar
- Perifera vaskulära sjukdomar
- Kranskärlssjukdom
- Myokardischemi
- Patologiska tillstånd, tecken och symtom
- Närings- och metabola sjukdomar
- Neoplasmer
- Hjärtsvikt
- Hypertoni
- Ischemi
- Diabetes mellitus
- Kardiomyopatier
- Perifer arteriell sjukdom
- Kranskärlssjukdom
- Kardiotoxicitet
- Administration
- Sjukvårdskvalitet, tillgång och utvärdering
- Hälsovårdskvalitet
- Kvalitetsindikatorer, hälsovård
- Vårdstandard
Andra studie-ID-nummer
- PRO00039290
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .